Mohamed Sherif Salem/LinkedIn
Nov 9, 2025, 11:35
Mohamed Sherif Salem: Anti-Xa Monitoring Did Not Reduce Bleeding or Thromboembolic Events
Mohamed Sherif Salem, Senior Clinical Pharmacist at Andalusia Health Egypt, shared on LinkedIn:
”A 2025 systematic review found that routine anti-factor Xa (anti-Xa) monitoring during therapeutic LMWH therapy led to more dose changes but did not reduce bleeding or thromboembolic events.
Study details:
- Design: Systematic review (4 randomized trials + 44 observational studies; total 48 studies).
- Key dataset: 30 studies ( >3,000 patients) evaluated the relationship between measured anti-Xa activity and bleeding risk.
Findings
- Anti-Xa measurements prompted dose adjustments more frequently than no monitoring.
- There was no reduction in clinical end points (major bleeding or thromboembolism) in monitored versus unmonitored groups.
- Correlation between anti-Xa levels and bleeding (or thrombotic) outcomes was weak or absent in most studies.
Interpretation / practical implications:
- Routine anti-Xa monitoring for patients on therapeutic LMWH cannot be recommended based on current evidence. The data support continuing fixed or weight-based dosing in typical patients.
- Monitoring should be selective: consider anti-Xa measurement in patients where LMWH pharmacokinetics are likely unreliable (examples: significant renal impairment, extremes of body weight, ongoing active bleeding or when clinical management would change based on the result).”
Article: A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
Authors: Tessa C.C. Jaspers, P. Christian Remmelzwaal, Eefje P.S. Weersink, Karina Meijer, Nakisa Khorsand

Read the full article here.
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 7, 2026, 16:26Shayan Mohammadmoradi: Excited to Co-Chair the 2028 Hemostasis Gordon Research Seminar
-
Aug 7, 2026, 16:04Ayuka King-Percival: Understanding Platelet Aggregation Testing
-
Aug 7, 2026, 15:59Nita Radhakrishnan։ New Evidence-Based Guidelines for Transfusion-Dependent Thalassemia
-
Aug 7, 2026, 15:54Seema Dawood: Why the Peripheral Blood Smear Still Matters in the Age of Automation?
-
Aug 7, 2026, 15:42Mohammed Elmourtada Abdulgayoom։ Caplacizumab-Enabled Treatment of iTTP Without Plasma Exchange
-
Aug 7, 2026, 15:40Renata Evertz: THUNDER Study Sets a New Benchmark in Stroke Thrombectomy
-
Aug 7, 2026, 15:23Ashley Brown: An Incredible Week at the Hemostasis GRC
-
Aug 7, 2026, 15:04Danique Steeghs: Developing a Chip-Sized ADAMTS13 Activity Assay for TTP Point-of-Care Testing
-
Aug 7, 2026, 15:02Mohd Laraib: The Importance of Multidisciplinary Collaboration in the Management of CAPS